Scientists have uncovered a molecular "on–off" switch that helps lung adenocarcinoma—the most common form of lung cancer—grow ...

Many lung cancers in nonsmokers have no known cause and are discovered only by chance.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

I was diagnosed with breast cancer, then lung cancer 17 years later — and both ultimately led me to make meaningful, positive ...

Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to lung adenocarcinoma cells, dramatically suppressing tumor growth in ...

As cancer cases have increased worldwide, the disease has become more complex, presenting challenges to scientific advances ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...

Researchers find that disrupted circadian rhythms may impair gut regeneration and microbiome balance, heightening colon ...

AI model calculates a protein-based stemness index to predict tumor aggressiveness and treatment resistance. Proteomic-based ...

Integrated pharmacokinetics (PK), exposure-response, safety, and efficacy data supported 6 mg/kg Q3W as the recommended Phase 2 dose (RP2D) of IBI343. This provides support for the conduct of ...